Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Novel aldose reductase inhibitor produced by Corynebacterium

Nov. 16, 1998

HIT study confirms the benefits of raising HDL cholesterol levels

Nov. 16, 1998

New compounds from Glaxo Wellcome and their use as beta3-adrenoceptor agonists

Nov. 13, 1998

Phase III trials with inhaled insulin begin in type I and II diabetics

Nov. 12, 1998

Evidence of cardiac valve abnormalities in Redux-treated patients still controversial

Nov. 12, 1998

Pharming to begin phase II trial of new Pompe's disease therapy

Nov. 12, 1998

First clinical trial of oral neurophilin compound in patients with diabetic neuropathy

Nov. 11, 1998

European phase III trial of Macritonin produces positive analysis of one-year BMD data

Nov. 11, 1998

Specific MC4 receptor agonist reduces food intake in leptin-deficient and -resistant mice

Nov. 10, 1998

WAY-135433 increases HDL cholesterol, protects against atherosclerosis and heart disease

Nov. 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.